Physician

Daniel Reif Greenwald, M.D.

According to 2025 Medicare claims, Daniel Greenwald, M.D. (NPI: 1235240987) practices medical oncology in the Santa Maria-Santa Barbara, CA market, with the plurality of this provider's patient population coming from Santa Barbara, CA. This provider's primary affiliated billing organization is THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (NPI: 1235107566; TIN: 954373071) and primary practice location at 93101-2018. Greenwald is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604) and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Greenwald's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 881 traditional Medicare patients, billed 244,884 HCPCS/CPT codes, and received $5,973,080 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 473 prescription claims across 139 beneficiaries totaling $1,183,591 in drug costs, led by Venclexta (Venetoclax). DME data shows 28 claims. Open Payments data shows 26 records totaling $21,467. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $2,253,901 to $5,973,080. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,597 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	546	187,118	$2,253,901
2016	580	156,295	$2,258,517
2017	563	137,838	$2,182,283
2018	612	174,053	$2,746,043
2019	672	199,151	$3,609,656
2020	666	224,010	$4,346,530
2021	697	184,523	$4,130,729
2022	843	185,217	$4,742,500
2023	835	205,500	$5,360,846
2024	881	244,884	$5,973,080

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	132	655	$1,171,977
2016	124	573	$1,064,092
2017	143	660	$1,030,270
2018	139	597	$1,745,203
2019	136	611	$2,030,497
2020	132	523	$2,790,495
2021	136	421	$1,900,764
2022	138	440	$1,737,488
2023	136	418	$1,131,140
2024	139	473	$1,183,591

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	16	139	$37,136
2016	15	121	$42,625
2017	26	69	$27,335
2018	N/R	11	$207
2019	N/R	37	$5,112
2020	12	82	$6,402
2021	N/R	N/R	N/R
2022	N/R	11	$538
2023	N/R	N/R	N/R
2024	N/R	28	$836

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	168	395	$146
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	636	1,427	$99
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	151	182	$13
36415	Insertion of needle into vein for collection of blood sample	240	647	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	252	804	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Venclexta	Venetoclax	14	382	$101,639
Abiraterone Acetate	Abiraterone Acetate	34	1,020	$12,763
Eliquis	Apixaban	13	495	$9,346
Dexamethasone	Dexamethasone	27	887	$610
Prednisone	Prednisone	61	2,305	$485

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$711
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$125

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$19,199	Genentech USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$2,268	F. Hoffmann-La Roche AG
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel Reif Greenwald, M.D.?

Tedicare shows public-source Medicare data for Daniel Reif Greenwald, M.D. (NPI 1235240987), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Reif Greenwald, M.D. have ACO affiliation data?

Daniel Reif Greenwald, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604) and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Daniel Reif Greenwald, M.D.?

Daniel Reif Greenwald, M.D. is linked to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (billing NPI 1235107566) in the available physician profile data.

Does Daniel Reif Greenwald, M.D. have Open Payments data?

Daniel Reif Greenwald, M.D. has 26 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.